Condition

Renal Cell Carcinoma (RCC) clinical trials and research

• 26Clinical trials
• 2NIH research projects
• 1New in 30 days
• 18Countries

Newest Renal Cell Carcinoma (RCC) clinical trials

All recruiting trials (26)

• Nectin-4 PET/CT imaging to differentiate renal tumors

  This study tests a new PET tracer, 18F-N230A, to see if it helps distinguish renal cell carcinoma from renal pelvic urothelial carcinoma in adults.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07875959

• Weight-loss programs to slow kidney cancer progression in small renal masses on active surveillance

  This study tests two weight-loss approaches, daily calorie restriction and 5:2 intermittent fasting, to see if they help people with small kidney tumors on active surveillance lose weight and potentially slow cancer progression.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT07714018

• Predicting Toripalimab Response in High-Risk Recurrent Renal Cell Carcinoma using MRD

  This study tests whether measuring minimal residual disease after surgery can predict which high-risk RCC patients will benefit from adjuvant Toripalimab.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07657325

• Safety and tolerability test of anti-CD70 T-cell therapy in advanced RCC

  This study tests a CD70-targeted CAR-T cell therapy in adults with advanced or metastatic renal cell carcinoma to see if it is safe and tolerable and to identify a usable dose for future studies.

  Recruiting Phase 1 Hrain Biotechnology Co., Ltd. · Shanghai · NCT07647744

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

• Laparoscopic versus open kidney removal: comparing outcomes and costs

  This trial will test whether laparoscopic (keyhole) kidney removal or open surgery gives better outcomes and lower costs for people needing a nephrectomy for a nonfunctioning kidney or localized kidney cancer.

  Recruiting Menoufia University · Shibīn al Kawm, Shebin Elkom · NCT07461090

• Phase 1 safety and tolerability testing of CTX-10726 in advanced cancers.

  This phase 1 trial will test whether CTX-10726 given by IV every two weeks is safe and tolerable for adults with advanced or metastatic renal cell carcinoma, hepatocellular carcinoma, endometrial, or gastroesophageal cancer who have exhausted standard treatments.

  Recruiting at 8 sites Phase 1 Compass Therapeutics · Phoenix, Arizona and 7 other locations · NCT07419841

• CBCT-guided markerless stereotactic radiotherapy for kidney cancer

  This project tests whether using CBCT imaging with breath-hold or surface-guided gating can deliver markerless SBRT more precisely for adults with non-metastatic kidney cancer.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland · NCT07402109

• Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors

  This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.

  Recruiting Phase 1 Sapu Nano (Us) LLC · Adelaide · NCT07369505

• 177Lu-TLX250 for advanced relapsed or recurrent clear-cell kidney cancer

  This will test whether 177Lu-TLX250, a CAIX-targeting radioligand, helps adults with CAIX-positive advanced or relapsed clear-cell kidney cancer who have had 2–3 prior therapies.

  Recruiting Phase 3 Telix Pharmaceuticals (Innovations) Pty Limited · Sydney, New South Wales and 4 other locations · NCT07197580

• PET/CT-guided treatment break for metastatic kidney cancer with favorable or intermediate IMDC risk

  This trial tries using PET/CT scans to guide temporary treatment breaks for people with metastatic kidney cancer (IMDC favorable or intermediate risk) who have had at least 12 months of combined PD-1/PD-L1 immunotherapy plus a VEGFR TKI and show a metabolic response.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT07175480

• GI-108 monotherapy for people with advanced or metastatic solid tumors

  We are testing GI-108 by itself to see if it is safe and can shrink tumors in people with advanced or metastatic solid tumors, including lung, head and neck, and pancreatic cancers.

  Recruiting at 3 sites Phase 1/2 GI Innovation, Inc. · Seoul and 2 other locations · NCT07172802

• Pre-surgery targeted artery embolization plus toripalimab and axitinib for advanced kidney cancer

  This test tries a targeted artery embolization one week before starting toripalimab plus axitinib to shrink advanced kidney tumors and improve outcomes for people preparing for surgery.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07172386

• A kidney cancer prediction model to guide treatment decisions, including for patients with tumor thrombus

  This project will test whether a new prediction model can guide treatment choices to improve survival for adults with renal cell carcinoma, including those with venous tumor thrombus.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07117227

• IBR854 plus pazopanib vs pazopanib in advanced kidney cancer

  This trial tests whether adding IBR854 to pazopanib helps people with advanced renal cell carcinoma compared with pazopanib alone.

  Recruiting Phase 2 Imbioray (Hangzhou) Biomedicine Co., Ltd. · Shanghai · NCT07087158

• Taking cabozantinib on a skip-days schedule instead of lowering the daily dose

  This test tries whether taking cabozantinib on a skip-days schedule gives similar drug levels, side effects, and quality of life for adults with metastatic renal cell carcinoma who are already on 20–40 mg daily.

  Recruiting Phase 2 Leiden University Medical Center · Leiden, South Holland · NCT07077161

• Looking at lymph nodes in kidney cancer

  This project will collect blood and tissue, including tumor and draining lymph nodes, from adults with known or suspected kidney cancer who are having routine procedures to see how T cells in lymph nodes interact with tumors.

  Recruiting Yale University · New Haven, Connecticut · NCT07038733

• Genomic profiling of prostate cancer in Native American men

  This project will test whether analyzing tumor and blood samples from men who identify as Native American can reveal genes that influence prostate cancer and treatment choices.

  Recruiting University of Oklahoma · Oklahoma City, Oklahoma · NCT06960798

• Using 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma

  This study is testing a new imaging method using a special dye to see if it can help doctors better diagnose kidney cancer and understand how a low-dose medication affects the images in patients.

  Recruiting The Affiliated Hospital of Qingdao University · Qingdao, Shandong · NCT06916624

• Evaluating SIM0505 for advanced solid tumors

  This study is testing a new treatment called SIM0505 to see if it is safe and effective for adults with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 6 sites Phase 1 NextCure, Inc. · Orlando, Florida and 16 other locations · NCT06792552

• Combining Tivozanib with Pembrolizumab for Kidney Cancer Treatment

  This study is testing if adding a cancer drug called tivozanib to the immunotherapy pembrolizumab can help people with high-risk kidney cancer live longer and feel better after their surgery.

  Recruiting at 409 sites Phase 3 Alliance for Clinical Trials in Oncology · Phoenix, Arizona and 428 other locations · NCT06661720

• High-dose Y-90 radioembolization for large kidney tumors

  This test uses high-dose Y-90 radioembolization to try to shrink or control kidney tumors larger than 4 cm in people who cannot have surgery.

  Recruiting Phase 2 Western University, Canada · London, Ontario · NCT06642220

• Evaluating GI-102 for advanced solid tumors with or without other cancer drugs

  This study is testing a new cancer treatment called GI-102, both on its own and with other cancer drugs, to see how safe it is and how well it works for people with advanced solid tumors.

  Recruiting at 11 sites Phase 1/2 GI Innovation, Inc. · Scottsdale, Arizona and 10 other locations · NCT05824975

• Evaluating AL8326 for advanced small cell lung cancer treatment

  This study is testing a new drug called AL8326 to see if it can help people with advanced small cell lung cancer who need a second treatment option.

  Recruiting at 5 sites Phase 2 Advenchen Laboratories, LLC · Birmingham, Alabama and 6 other locations · NCT05363280

• Zanzalintinib with immune checkpoint drugs for advanced solid tumors

  This trial will test whether zanzalintinib alone or combined with immune drugs (nivolumab, with or without ipilimumab or relatlimab) is safe and helps people with advanced or metastatic solid tumors such as renal cell, prostate, urothelial, and liver cancers.

  Recruiting at 101 sites Phase 1 Exelixis · Phoenix, Arizona and 121 other locations · NCT05176483

NIH-funded research (2)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Exploring a new boron-based treatment for kidney cancer

  This study is looking at a new treatment that could help people with clear cell kidney cancer by blocking a specific pathway that makes the cancer grow, and they're testing different versions of a compound to find the best one for this purpose.

  NIH research University of Missouri Kansas City · Kansas City, United States · NIH-10947752

• Improving kidney cancer treatment by enhancing immune response

  This study is looking at how to help your immune system better fight kidney cancer by understanding a protein that helps cancer cells survive, with the hope of improving current treatments for patients like you.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-10721156

Related topics

Quick answers

How many Renal Cell Carcinoma (RCC) clinical trials are recruiting right now?

26, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 18 countries. The most sites are in United States (10 trials), China (9 trials), Australia (3 trials), Netherlands (3 trials), South Korea (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 1: 5, Phase 1/2: 3, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →